National Institute of Allergy and Infectious Diseases


The Path to a Cure for Hepatitis C in People with HIV

NIH logo

Hepatitis C can be a chronic condition that leads to liver failure, and treatments often haven’t worked for patients who are also co-infected with HIV. Thanks to research led by the National Institute of Allergy and Infectious Diseases and Gilead Sciences, new therapies are now available that can cure even complicated cases of hepatitis C…

Curing Hard-to-Treat Hepatitis C


In a new video, NIH researchers and their colleagues from health centers in the District of Columbia discuss efforts to improve treatments for hepatitis C, a potentially life-threatening viral disease that slowly damages the liver. NIH-sponsored clinical studies in the nation’s capital focus on identifying effective, safe, and convenient therapies for hard-to-treat hepatitis C patients,…

BULLETIN: HIV Vaccine Awareness Day 2015

nih logo

May 18, 2015 Vaccination has historically been the best method for protecting against and ultimately defeating mankind’s most devastating infectious diseases. Although the path to developing a safe and effective HIV vaccine has so far been difficult, achieving this goal remains key to realizing a durable end to the global HIV/AIDS pandemic. HIV vaccine development…

HIV Vaccine Awareness Day

Dr. Anthony Fauci

Watch NIAID Director Anthony S. Fauci, M.D., discuss current HIV vaccine research approaches. Developing a safe and sufficiently effective HIV vaccine is essential if we are to achieve a timely and durable end to the global HIV/AIDS pandemic. The path to an HIV vaccine has not been—and will not be—an easy one. In the 27…

NIH Seeks Input on HIV Cure Research Priorities

nih logo

The National Institutes of Health (NIH) is asking the scientific community to weigh in on what should be the highest priority research areas related to understanding HIV persistence and investigating strategies for eradicating or controlling remaining virus despite optimal antiretroviral treatment. Responses will be accepted through March 14 and will help guide the HIV Cure Initiative, a $100 million…

MEDIA AVAILABILITY: Durable End to AIDS Will Require HIV Vaccine Development


Recent Scientific Advances Offer Promising Areas for Further Exploration   WHAT: Broader global access to lifesaving antiretroviral therapies and wider implementation of proven HIV prevention strategies could potentially control and perhaps end the HIV/AIDS pandemic. However, a safe and at least moderately effective HIV vaccine is needed to reach this goal more expeditiously and in…

NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks

nih logo

The National Institute of Allergy and Infectious Diseases (NIAID) has selected the principal investigators and clinical trials units (CTUs) that will lead and conduct the research of the five restructured HIV/AIDS clinical trials networks through 2021. The new structure is designed to create a broader, more flexible and more collaborative approach to the networks’ research priorities, which…

NIH announces plan to increase funding toward a cure for HIV/AIDS

NIH logo

At a White House event today to mark the 25th annual World AIDS Day, President Obama announced that the National Institutes of Health plans to redirect AIDS research funds to expand support for research directed toward a cure for HIV. NIH plans to invest an additional $100 million over the next three fiscal years on this increasingly promising area…